

Use of the olefin metathesis reaction for highly efficient β -cyclodextrin modification

Bernard Bertino Ghera,^a Fabienne Fache^b and H el ene Parrot-Lopez^{a,*}

^aLaboratoire de Chimie Organique 2, Glycochimie UMR-CNRS 5181, Universit e Lyon 1, B at J. Raulin, 43 Bd du 11 Novembre 1918, Villeurbanne cedex, France

^bChimie Organique, Photochimie et Synth ese UMR-CNRS 5181, Universit e Lyon 1, B at J. Raulin, 43 Bd du 11 Novembre 1918, Villeurbanne cedex, France

Received 3 February 2006; revised 1 March 2006; accepted 3 March 2006
Available online 3 April 2006

Abstract—A series of novel primary face mono-substituted β -cyclodextrin derivatives have been synthesised using the olefin metathesis reaction. Mono-6-allylamino-6-deoxy- β -cyclodextrin easily synthesised by nucleophilic substitution of mono-6-tosyl- β -cyclodextrin is the key synthon in the preparation of cyclodextrin derivatives mono-functionalised at the primary face by alkyl, aryl or perfluoroalkyl groups using Grubbs catalyst. In the cases of vinylbenzene and 1H,1H,2H-perfluoro-1-octene, the metathesis reactions yield with 95% stereoselectivity of the *E*-isomer.

  2006 Elsevier Ltd. All rights reserved.

1. Introduction

Olefin metathesis is one of the most powerful synthetic tools in organic chemistry, with a large scope of applications from natural product to polymer synthesis.^{1–4} More specifically, this reaction has been applied with success to carbohydrate chemistry.^{5,6} In the particular case of cyclodextrins (CDs) or cyclomaltoheptaoses, only a few examples have been reported so far. Thus, in 2000, Stoddart et al.⁷ described the use of olefin metathesis to generate face-to-face 2-2' and 3-3' dimers of β -cyclodextrin. This was achieved by a homodimerisation reaction between mono-substituted cyclodextrins having ethylene oxy-alkene groups present at either the O-2 or the O-3 positions.

Following this, in 2002, Sin ay et al. synthesised 'head-to-head' dimers of α - and β -cyclodextrin using mono-substitution at the O-6 position with alkylidene chains.^{8–10} More recently, the same authors described the synthesis of a heteroduplex system containing both α - and β -cyclodextrin disubstituted units using the metathesis reaction.¹¹

Generally, the introduction of bioactive substituents onto the cyclodextrins has been treated in a case by case manner, with each coupling specific to the introduced recognition

antenna. This has been achieved using esters,¹² amides¹³ or thioalkyl¹⁴ linkages with success. However, linkages using ether or amine functions are much more difficult. In order to make the introduction of antenna more efficient and allow rapid generation of libraries of such molecules, a 'base unit' consisting of a mono-substituted cyclodextrin capable of accepting a wide range of antennae under a standard coupling condition would seem to be highly attractive.

In this work, we describe an efficient synthesis by olefin metathesis reaction of new β -cyclodextrin derivatives mono-substituted at the primary face by different hydrophilic or hydrophobic chains linked by a nitrogen atom at the C-6 position. This reaction opens up the facile synthesis of a wide range of CDs derivatives using one simple building block.

2. Results and discussion


2.1. Synthesis and characterisation

The synthetic procedure for the synthesis of the new β -cyclodextrin derivatives **9**, **10**, **11**, **12** mono-functionalised at the primary face by different groups (oct-1-ene, vinylbenzene, 3-(2-methoxyethoxy)-prop-1-ene, 1H,1H,2H-perfluoro-1-octene) and the homodimer **13** was based on an olefin metathesis reaction in four steps from mono-6-allylamino-6-deoxy- β -cyclodextrin **1** (Scheme 1).¹⁵

The use of the Grubbs catalyst requires protection of the nitrogen atom and the lack of solubility of **1** in organic solvents

Keywords: β -Cyclodextrin; Metathesis reaction; Mono-functionalisation.

* Corresponding author at present address: UMR-CNRS 5181, M ethodologie de Synth ese et Mol ecules Bioactives, Universit e Lyon 1, Domaine Scientifique de la Doua, B at. J. Raulin, 43 Bd du 11 Novembre 1918, 69622 Villeurbanne cedex, France. Tel.: +33 472431532; fax: +33 472431508; e-mail: helene.parrot@univ-lyon1.fr



Scheme 1. Reagents and conditions: (i) Boc_2O , NaHCO_3 , MeOH , ultrasonication; (ii) NaH , CH_3I , DMF , 20°C ; (iii) oct-1-ene, Grubbs catalyst $[\text{Cl}_2(\text{PCy}_3)_2\text{Ru}=\text{CHPh}]$, CH_2Cl_2 , 55°C ; (iv) vinylbenzene, $[\text{Cl}_2(\text{PCy}_3)_2\text{Ru}=\text{CHPh}]$, CH_2Cl_2 , 55°C ; (v) 3-(2-methoxyethoxy)-prop-1-ene, $[\text{Cl}_2(\text{PCy}_3)_2\text{Ru}=\text{CHPh}]$, CH_2Cl_2 , 55°C ; (vi) 1H,1H,2H-perfluoro-1-octene, Grubbs–Hoveyda catalyst $(\text{C}_{31}\text{H}_{38}\text{Cl}_2\text{N}_2\text{ORu})$, CH_2Cl_2 , 55°C ; (vii) $[\text{Cl}_2(\text{PCy}_3)_2\text{Ru}=\text{CHPh}]$, CH_2Cl_2 , 55°C ; (viii) TFA, 20°C .




Figure 1. (A) ^1H NMR spectrum of **7**; (B) ^1H with ^{19}F decoupled NMR spectrum of **7**.

necessitates modification of the free hydroxyl groups at the O-2, O-3 and O-6 positions. N-protection was carried out using di-*tert*-butyl dicarbonate (Boc_2O) according to the conditions of peptide synthesis¹⁶ to give **2** in 67% isolated yield. O-methylation at the six primary hydroxyl groups and the fourteen secondary hydroxyl groups of the β -CD **2** was realised using of 50 equiv of methyl iodide in dry DMF with 60 equiv of sodium hydride. The new cyclodextrin derivative **3** was purified by flash chromatography (eluent gradient $\text{CHCl}_3/\text{acetone}$, 100/0 to 60/40) in 67% isolated yield. The degree of the substitution was assessed by MALDI mass spectrometry (m/z 1576.7 $[\text{M}+\text{Na}]^+$ 1592.7 $[\text{M}+\text{K}]^+$) and the structure confirmed by ^1H , ^{13}C and HMBC NMR spectroscopy.

Mono(6^{A} -*N*-allyl-*N*-*tert*-butoxycarbonylamino, 6^{A} -deoxy)-hexakis(6^{B} , 6^{C} , 6^{D} , 6^{E} , 6^{F} , 6^{G} -*O*-methyl)-heptakis(2,3-di-*O*-methyl)- β -cyclodextrin **3** (0.25 M in CH_2Cl_2) in the presence of the Grubbs catalyst $[\text{Cl}_2(\text{PCy}_3)_2\text{Ru}=\text{CHPh}]$ (15% mol/mol for **4** and **5**, 20% mol/mol for **6**) was reacted at 55 °C, under argon, with oct-1-ene, vinylbenzene or 3-(2-methoxyethoxy)-prop-1-ene¹⁷ (2.5 equiv) during 18 h for **4** and **5**, 46 h for **6**. The cyclodextrins derivatives **4**, **5** and **6** were isolated by flash chromatography on silica gel with eluent gradient $\text{Et}_2\text{O}/\text{MeOH}$ 100/0 to 96/4 for **4** and **5**, 100/0 to 95/5 for **6**, in 70, 73 and 53% yields, respectively. The coupling of the olefins was confirmed via ^1H NMR spectroscopy (500 MHz, solvent CDCl_3) by the changes in the chemical shifts of the vinylic protons situated at C-2' and C-3'. The signal for the proton H-3' shows the largest perturbation, being shifted downfield (5.46–6.38 ppm) in the new

compounds **4**, **5** and **6** with respect to initial values (m, 4.95–5.07 ppm) in *N*-Boc-allyl-amino β -cyclodextrin **3**. Mono-substitution of β -cyclodextrin by a long chain, which may be hydrophobic or hydrophilic, is known to reduce the geometry of the cavity. This leads to a separation in the peaks for H-1 (m, 4.94–5.11 ppm) into three signals; a broad singlet at 4.94 ppm, integration 1, a multiplet around 5.03 ppm, integration 5 and a broad singlet at 5.11 ppm, integration 1. In the case of coupling with vinylbenzene there is less perturbation, one signal at 5.12 ppm, integration 1 and a second at 5.03 ppm, integration 6.

Determination of the *E*, *Z* selectivity of this reaction is not trivial as the signals of the vinylic protons of compounds **4** and **6** are present as multiplets. However for β -cyclodextrin derivative **5**, the coupling constant H-2'/H-3' at 15.0 Hz confirms *E* geometry. The metathesis reaction yields stereoselectively (95%) the *E*-isomer,[†] in 73% yield, which is interesting when compared to the generally measured ratio *E/Z* isomer (7/3). It should be noted that in the case of the ether-linked 3-3'- β -CD dimer described by Stoddart, the authors concluded after much work, that the isomers were present in the 9:1 ratio.⁷

Given the facile nature of the above synthesis, we applied the reaction to the introduction of perfluoroalkyl chains, leading to the synthesis of the β -CD derivative **7**. Only few examples of metathesis have been published so far with fluorinated

[†] The actual ratio, as determined, is within the experimental limits of incertitude for ^1H NMR spectroscopy.

olefins with one or two fluorine atoms^{18,19} or with longer fluorinated chains.^{20,21} In previous studies, we have synthesised mono-fluorinated amphiphilic cyclodextrin from mono-6-tosyl- β -cyclodextrin with 3-perfluorohexylpropanethiol by nucleophilic attack at the tosyl group.²² Introduction of perfluoroalkyl chains in carbohydrates has been carried out using radical reactions from allylic compounds.²³ This method is not available for the cyclodextrins.²⁴ The novel derivative **7** was synthesised by a metathesis reaction between the olefinic cyclodextrin derivative **3** and 13 equiv of the 1H,1H,2H-perfluoro-1-octene in presence of the Grubbs–Hoveyda catalyst²⁵ ($C_{31}H_{38}Cl_2N_2ORu$) in CH_2Cl_2 at 55 °C for 9 days. Purification by flash chromatography yields **7** and the cyclodextrin dimer **8**. However, we have directly isolated **8** by the homodimerisation of the cyclodextrin derivative **3** in presence of the first generation Grubbs catalyst (14% mol/mol) at 50 °C for 21 h in 60% yield. Comparing the above results we propose that **8** is first synthesised as the kinetic product, which then reacts with the fluorinated olefin to give **7**. Stereoselectivity of the metathesis reaction is again confirmed by NMR in $CDCl_3$ of **7**. In the 1H decoupled ^{19}F spectrum (Fig. 1B) the appearance of a multiplet for H-2' at 6.32 ppm and a doublet for H-3' at 5.58 ppm with the coupling constant H-2'/H-3'=16 Hz is characteristic of the *E*-isomer. The anomeric signal H-1 was converted from a multiplet to a doublet ($^3J_{H-1/H-2}=3.5$ Hz). In the ^{13}C NMR C-2' and C-3' were observed at 139.4 and 117.5 ppm, respectively. Analysis by electrospray mass spectrometry (ESMS) confirms the structure of **7** (m/z 1894.9 $[M+Na]^+$ 959.0 $[M+2+Na]^{2+}$).

Selective removal of the *N*-Boc protecting group by trifluoroacetylation (TFA, 20 °C) to gives the secondary amino cyclodextrin derivatives **9**, **10**, **11**, **12** and **13** in 94, 82, 94, 89 and 91% yields, respectively.

3. Conclusion

We have synthesised a variety of primary face mono-substituted β -cyclodextrin derivatives by the use of the metathesis reaction. This reaction gives direct access to β -cyclodextrin derivatives via a single synthon mono-6-allyl-6-deoxy- β -cyclodextrin **1** and various olefins presenting hydrophobic or hydrophilic nature. We also show the feasibility of this synthesis for the coupling of perfluoroalkyl-olefin. In the cases of vinylbenzene and 1H,1H,2H-perfluoro-1-octene, we obtained the *E*-isomer in 95% whereas the previous best stereoselectivities observed in the chemistry of cyclodextrins were 9:1. This metathesis reaction presents a highly promising route to novel mono-functionalised cyclodextrin derivatives.

4. Experimental

4.1. General

Ruthenium catalysts were purchased from Aldrich. β -Cyclodextrin was generously provided by Roquette (France). 1H , ^{13}C , COSY, HSQC and HMBC NMR experiments were performed at 300 and 75 MHz, respectively, or 500 and 125 MHz, respectively, using a Bruker DRX 300 spectrometer or a Bruker AM 500 spectrometer. ^{19}F NMR experiments were obtained at 280 MHz with a Bruker ALS 300

spectrometer. It should be noted that mono-substitution of any cyclodextrin totally removes the axial symmetry of the molecule leading to considerable overlap in closely related chemical shifts of every proton or carbon and rendering spectral analysis extremely complex. ES mass spectra were measured using a Perkin–Elmer Sciex spectrometer and MALDI-TOF mass spectra were measured using Applied Biosystems Voyager-DE Pro. IR spectra were recorded on a Perkin–Elmer instrument. The optical rotations were tested on a Perkin–Elmer 241 Polarimeter.

4.1.1. Mono-(6^A-*N*-allylamino-6^A-deoxy)-cyclomaltoheptaose **1.** The mono-(6^A-deoxy-6^A-(*p*-toluenesulfonyl)-cyclomaltoheptaose²⁶ was converted into **1** by the procedure described by Lai and Ng.¹⁵ Yield: 81%; R_f (*n*-BuOH/EtOH/H₂O, 5/4/3)=0.06; mp: >250 °C; $[\alpha]_D$ +138 (*c* 1.000, MeOH); IR (cm^{-1} , KBr): 3395 (O–H), 2927 (C–H), 1657 (C=C), 1158 (C–O–C), 1033 (C–N); 1H NMR (DMSO-*d*₆, 300 MHz, assignments by HSQC): δ (ppm): 2.69 (m, 1H, H-6aA), 2.92 (m, 1H, H-6bA), 3.18 (m, 2H, H-1'), 3.32–3.40 (m, 14H, H-4, H-5), 3.53–3.63 (m, 26H, H-2, H-3, H-6a, H-6b), 4.44 (br s, 6H, OH-6), 4.83 (br s, 7H, H-1), 5.03 (d, 1H, H-3'b, $^3J_{H-3'b/H-2'}=10.1$ Hz), 5.14 (d, 1H, H-3'a, $^3J_{H-3'a/H-2'}=17.7$ Hz), 5.67–5.81 (m, 15H, OH-2, OH-3, H-2'); ^{13}C NMR (DMSO-*d*₆, 75 MHz, assignments by HSQC): δ (ppm): 49.8 (C-6A), 52.5 (C-1'), 60.8 (C-6), 72.8 (C-2), 73.3 (C-5), 73.9 (C-3), 82.1–82.4 (C-4), 84.7 (C-4A), 102.8–103.1 (C-1), 116.1 (C-3'), 138.3 (C-2'); ESMS (+) m/z : $[M+Na]^+$ 1197.2; $C_{45}H_{75}NO_{34}$.

4.1.2. Mono-(6^A-*N*-allyl-*N*-tert-butoxycarbonylamino-6^A-deoxy)-cyclomaltoheptaose **2.** To a solution of **1** (2.00 g, 1.70 mmol) in MeOH (50 mL) at room temperature were added Boc₂O (0.45 g, 2.05 mmol, 1.2 equiv) and NaHCO₃ (0.43 g, 5.11 mmol, 3 equiv). The reaction mixture was placed for 12 h in an ultrasonic bath and monitored by TLC. The solvent was evaporated and the white solid was purified by column chromatography (Silica gel 100 C₁₈-reversed phase, H₂O/MeOH, step gradient: 100/0 to 50/50) to afford **2** as a white powder. Yield: 67%; R_f (*n*-BuOH/EtOH/H₂O, 5/4/3)=0.44; mp: 206 °C; $[\alpha]_D$ +132 (*c* 1.015, MeOH); IR (cm^{-1} , KBr): 3395 (O–H), 2918 (C–H), 1676 (C=O), 1155 (C–N), 1028 (C–O–C); 1H NMR (MeOD-*d*₄, 500 MHz, assignments by COSY and HSQC): δ (ppm): 1.51 (s, 9H, CH₃ Boc), 2.84 (dd, 1H, H-6aA, $^2J_{H-6aA/H-6bA}=14.5$ Hz and $^3J_{H-6aA/H-5A}=10.5$ Hz), 3.18 (t, 1H, H-4A, $^3J_{H-4A/H-3A}=^3J_{H-4A/H-5A}=9.5$ Hz), 3.50–3.74 (m, 20H, H-2, H-4, H-5, H-1'b), 3.79–4.03 (m, 21H, H-3, H-6a, H-6b), 4.26 (t, 1H, H-5A, $^3J_{H-5A/H-4A}=^3J_{H-5A/H-6bA}=10.3$ Hz), 4.46 (d, 1H, H-1'a, $^2J_{H-1'a/H-1'b}=14.5$ Hz), 4.97–5.03 (m, 7H, H-1), 5.15 (m, 2H, H-3'), 5.80 (m, 1H, H-2'); ^{13}C NMR (MeOD-*d*₄ and 10% of Pyridine-*d*₅, 125 MHz, assignments by DEPT and HSQC): δ (ppm): 27.9, 28.6 (CH₃ Boc), 48.3 (C-6A), 51.8 (C-1'), 60.8 (C-6), 70.6 (C-5A), 72.4–74.1 (C-2, C-3, C-5), 80.1 (O–C Boc), 82.1–82.5 (C-4), 85.3 (C-4A), 101.7 (C-1A), 102.8–103.4 (C-1), 115.1 (C-3'), 134.1 (C-2'), 155.8 (–C=O Boc); ESMS (+) m/z : $[M+Na]^+$ 1296.4, $[M+H]^+$ 1275.4; $C_{50}H_{83}NO_{36}$.

4.1.3. Mono-(6^A-*N*-allyl-*N*-tert-butoxycarbonylamino-6^A-deoxy)-hexakis-6^B,6^C,6^D,6^E,6^F,6^G-*O*-methyl)-heptakis-(2,3-di-*O*-methyl)-cyclomaltoheptaose **3.** NaH 60% (4.70 g, 117.6 mmol, 60 equiv, 3 equiv/OH) was added to

a solution of **2** (2.50 g, 1.9 mmol) in DMF (40 mL). The mixture was stirred for 3 h, then ICH₃ (6.10 mL, 98 mmol, 50 equiv, 2.5 equiv/OH) was added dropwise to the suspension (the temperature must be kept below 35 °C). After stirring for 18 h at room temperature, excess NaH was destroyed carefully by addition of methanol (10 mL) and the solution was diluted with water (50 mL). The organic layer was extracted with diethyl ether (3×100 mL). The combined organic layers were washed with water, dried over Na₂SO₄. The solvent was evaporated and the yellow solid was subjected to column chromatography (SiO₂, CHCl₃/acetone, step gradient: 100/0 to 60/40) to afford **3**. Yield: 65%; *R_f* (Et₂O/MeOH, 90/10)=0.26; mp: 80 °C; [α]_D+140 (c 1.025, CHCl₃); IR (cm⁻¹, KBr): 2930 (C–H), 1700 (C=O), 1164 (C–O–C), 1037 (C–N); ¹H NMR (CDCl₃, 300 MHz, assignments by COSY and HSQC): δ (ppm): 1.43 (s, 9H, CH₃ Boc), 2.86 (m, 1H, H-6aA), 3.10–3.13 (m, 8H, H-2, H-4A), 3.31–3.81 (m, 93H, H-3, H-4, H-5, H-6a, H-6b, 2-OCH₃, 3-OCH₃, 6-OCH₃, H-1'b), 4.01 (m, 1H, H-5A), 4.28 (m, 1H, H-1'a), 4.95–5.07 (m, 9H, H-1 and H-3'), 5.69 (m, 1H, H-2'); ¹³C NMR (CDCl₃, 75 MHz, assignments by DEPT and HSQC): δ (ppm): 28.8–29.3 (CH₃ Boc), 49.2 (C-6A), 51.3 (C-1'), 58.5–62.1 (2-OCH₃, 3-OCH₃, 6-OCH₃), 71.0–71.8 (C-5, C-6), 79.7 (O–C Boc), 80.7–82.4 (C-2, C-3, C-4), 98.4 (C-1A), 99.4–100.5 (C-1), 116.5 (C-3'), 134.1 (C-2'), 155.3 (C=O Boc); MALDI-TOF-MS: [M+Na]⁺ 1576.7, [M+K]⁺ 1592.7; C₇₀H₁₂₃NO₃₆.

4.1.4. General procedure for metathesis reactions. To a solution of **3** (1.0 equiv) in freshly distilled CH₂Cl₂ (0.25 M) was added under argon the alkene (2.5 equiv) and Grubbs catalyst [Cl₂(PCy₃)₂Ru=CHPh] (15% mol/mol for **4**, **5** and 20% mol/mol for **6**). The solution was stirred at 50 °C and the reaction can be monitored by TLC (Et₂O/MeOH, 90/10). After stirring for 18 h (46 h for **6**), the solvent was evaporated and the black solid was subjected to column chromatography (SiO₂, Et₂O/MeOH, step gradient: 100/0 to 96/4 (100/0 to 95/5 for **6**) to afford the product.

4.1.4.1. Mono-(6^A-deoxy-6^A-(1-*N*-non-2-ene-*N*-tert-butoxycarbonylamino))-hexakis-(6^B,6^C,6^D,6^E,6^F,6^G-*O*-methyl)-heptakis-(2,3-di-*O*-methyl)-cyclomaltoheptaose **4.** Yield: 70%; *R_f* (Et₂O/MeOH, 90/10)=0.63; mp (dec): 68 °C; [α]_D+133 (c 0.990, CHCl₃); IR (cm⁻¹, KBr): 2929 (C–H), 1697 (C=O), 1164 (C–O–C), 1037 (C–N); ¹H NMR (CDCl₃, 500 MHz): δ (ppm): 0.81 (s, 3H, H-9', H-8'), 1.43 (s, 9H, CH₃ Boc), 1.98 (q, 2H, H-4'), ³J_{H-4'/H-5'}=³J_{H-4'/H-3'}=7.0 Hz), 2.75 (m, 1H, H-6aA), 3.04 (t, 1H, H-4A), ³J_{H-4A/H-5A}=³J_{H-4A/H-3A}=9.0 Hz), 3.09–3.13 (m, 7H, H-2), 3.30–3.82 (m, 93H, H-3, H-4, H-5, H-6a, H-6b, 2-OCH₃, 3-OCH₃, 6-OCH₃, H-1'b), 4.03 (m, 1H, H-5A), 4.35 (d, 1H, H-1'a), ²J_{H-1'a/H-1'b}=13.0 Hz), 4.94 (br s, 1H; H-1), 5.03 (m, 5H, H-1), 5.11 (br s, 1H, H-1), 5.30 (m, 1H, H-2'), 5.46 (m, 1H, H-3'); ¹³C NMR (CDCl₃, 125 MHz): δ (ppm): 14.5 (C-9'), 23.0 (C-8'), 28.9–29.6 (C-5', C-6', CH₃ Boc), 32.1 (C-7'), 32.7 (C-4'), 48.9 (C-6A), 51.2 (C-1'), 58.8–62.1 (2-OCH₃, 3-OCH₃, 6-OCH₃), 71.0–72.0 (C-5, C-6), 79.5 (O–C Boc), 80.7–82.6 (C-2, C-3, C-4), 98.4 (C-1A), 99.8–100.5 (C-1), 133.4 (C-2'), 133.9 (C-3'), 155.3 (C=O Boc); MALDI-TOF-MS [M+Na]⁺ 1662.7, [M+K]⁺ 1676.7; C₇₆H₁₃₅NO₃₆.

4.1.4.2. Mono-(6^A-deoxy-6^A-(1-*N*-3-phenyl-prop-2-ene-*N*-tert-butoxycarbonylamino))-hexakis-(6^B,6^C,6^D,6^E,6^F,6^G-*O*-methyl)-heptakis-(2,3-di-*O*-methyl)-cyclomaltoheptaose **5.** Yield: 73%; *R_f* (Et₂O/MeOH, 90/10)=0.55; mp (dec): 95 °C; [α]_D+135 (c 1.005, CHCl₃); IR (cm⁻¹, KBr): 2930 (C–H), 1700 (C=O), 1170 (C–O–C), 1036 (C–N); ¹H NMR (CDCl₃, 500 MHz): δ (ppm): 1.46 (s, 9H, CH₃ Boc), 2.80 (m, 1H, H-6aA), 3.07–3.13 (m, 8H, H-2, H-4A), 3.29–3.85 (m, 93H, H-3, H-4, H-5, H-6a, H-6b, 2-OCH₃, 3-OCH₃, 6-OCH₃, H-1'b), 4.06 (m, 1H, H-5A), 4.57 (d, 1H, H-1'a), ²J_{H-1'a/H-1'b}=14.0 Hz), 5.03 (m, 6H, H-1), 5.12 (br s, 1H, H-1A), 6.08 (m, 1H, H-2'), 6.38 (d, 1H, H-3', ³J_{H-3'/H-2'}=15.0 Hz), 7.16 (t, 1H, H-para, ³J_{H-para/H-meta}=7.3 Hz), 7.24 (t, 2H, H-meta, ³J_{H-meta/H-para}=³J_{H-meta/H-ortho}=7.3 Hz), 7.30 (d, 2H, H-ortho, ³J_{H-ortho/H-meta}=7.3 Hz); ¹³C NMR (CDCl₃, 125 MHz): δ (ppm): 28.9–29.4 (CH₃ Boc), 49.5 (C-6A), 51.5 (C-1'), 58.0–62.3 (2-OCH₃, 3-OCH₃, 6-OCH₃), 71.1–71.5 (C-5, C-6), 79.7 (O–C Boc), 81.9–82.6 (C-2, C-3, C-4), 98.5 (C-1A), 99.6–100.6 (C-1), 125.6 (C-3'), 126.7 (C-ortho), 128.1 (C-para), 129.0 (C-meta), 132.1 (C-2'), 137.0 (C-ipso), 155.3 (C=O Boc); MALDI-TOF-MS [M+Na]⁺ 1652.9, [M+K]⁺ 1668.9; C₇₆H₁₂₇NO₃₆.

4.1.4.3. Mono-[6^A-deoxy-6^A-(1-*N*-5,8-dioxy-non-2-ene-*N*-tert-butoxycarbonylamino))-hexakis-(6^B,6^C,6^D,6^E,6^F,6^G-*O*-methyl)-heptakis-(2,3-di-*O*-methyl)-cyclomaltoheptaose **6.** Yield: 53%; *R_f* (Et₂O/MeOH, 90/10)=0.20; mp (dec): 76 °C; [α]_D+113 (c 1.005, CHCl₃); IR (cm⁻¹, KBr): 2928 (C–H), 1698 (C=O), 1164 (C–O–C), 1038 (C–N); ¹H NMR (CDCl₃, 500 MHz, assignments by COSY and HSQC): δ (ppm): 1.43 (s, 9H, CH₃ Boc), 2.71 (m, 1H, H-6aA), 3.03 (t, 1H, H-4A), ³J_{H-4A/H-5A}=³J_{H-4A/H-3A}=9.0 Hz), 3.10–3.12 (m, 7H, H-2), 3.31–3.84 (m, 100H, H-3, H-4, H-5, H-6a, H-6b, 2-OCH₃, 3-OCH₃, 6-OCH₃, H-1'b, H-6', H-7', H-9'), 4.01 (m, 4H, H-4', H-5A), 4.46 (d, 1H, H-1'a), ²J_{H-1'a/H-1'b}=13.5 Hz), 4.94 (br s, 1H, H-1A), 5.03 (m, 5H, H-1), 5.11 (br s, 1H, H-1), 5.60 (m, 2H, H-2', H-3'); ¹³C NMR (CDCl₃, 125 MHz, assignments by DEPT and HSQC): δ (ppm): 28.9–29.4 (CH₃ Boc), 49.2 (C-6A), 50.9 (C-1'), 58.5–62.2 (2-OCH₃, 3-OCH₃, 6-OCH₃, C-9'), 69.9 (C-6'), 70.2–72.0 (C-5, C-6, C-7'), 72.3 (C-4'), 79.6 (O–C–Boc), 81.3–83.1 (C-2, C-3, C-4), 84.4 (C-4A), 98.5 (C-1A), 99.6–100.0 (C-1), 129.2 (C-2, C-3'), 155.2 (C=O Boc); HR-MALDI-TOF-MS [M+Na]⁺ 1664.8884, [M+K]⁺ 1680.8875; C₇₄H₁₃₁NO₃₈.

4.1.5. Mono-[6^A-deoxy-6^A-(1-*N*-3-perfluorohexylprop-2-ene-*N*-tert-butoxycarbonylamino))-hexakis-(6^B,6^C,6^D,6^E,6^F,6^G-*O*-methyl)-heptakis-(2,3-di-*O*-methyl)-cyclomaltoheptaose **7.** To a solution of **3** (0.25 M) in freshly distilled CH₂Cl₂ (0.390 g, 0.251 mmol) and 1H,1H,2H-perfluoro-1-octene (73 μL, 3.220 mmol, 13 equiv) was added under argon Hoveyda–Grubbs catalyst (C₃₁H₃₈Cl₂N₂ORu) (32 mg, 51 μmol, 20% mol/mol). The solution was stirred at 50 °C and the reaction can be monitored by TLC (Et₂O/MeOH, 90/10). After stirring for 9 days, the solvent was evaporated and the black solid was subjected to column chromatography (SiO₂, Et₂O/MeOH, step gradient: 100/0 to 95/5) to afford **7**. Yield: 27%; *R_f* (Et₂O/MeOH, 90/10)=0.80; mp (dec): 74 °C; [α]_D+111 (c 0.670, CHCl₃); IR (cm⁻¹, KBr): 2932 (C–H), 1701 (C=O), 1243–1180 (C–F), 1165 (C–O–C), 1039 (C–N); ¹H NMR (CDCl₃, 500 MHz, assignments by COSY and HSQC): δ (ppm):

1.43 (s, 9H, CH₃ Boc), 2.73 (m, 1H, H-6aA), 3.08–3.10 (m, 8H, H-2, H-4A), 3.27–3.85 (m, 93H, H-3, H-4, H-5, H-6a, H-6b, 2-OCH₃, 3-OCH₃, 6-OCH₃, H-1'b), 4.00 (m, 1H, H-5A), 4.58 (m, 1H, H-1'a), 5.02–5.04 (m, 7H, H-1), 5.58 (m, 1H, H-3'), 6.32 (d, 1H, H-2', ³J_{H-2'/H-3'}=16.0 Hz); ¹³C NMR (CDCl₃, 125 MHz, assignments by DEPT and HSQC): δ (ppm): 28.6–29.2 (CH₃ Boc), 50.1 (C-6A, C-1'), 58.3–61.9 (2-OCH₃, 3-OCH₃, 6-OCH₃), 71.2–72.0 (C-5, C-6), 80.3 (–O–C– Boc), 81.1–83.8 (C-2, C-3, C-4), 98.4 (C-1A), 99.7–100.7 (C-1), 108.4–118.7 (C-4', C-5', C-6', C-7', C-8', C-9'), 117.5 (C-3'), 139.4 (C-2'), 155.6 (–C=O Boc); ¹⁹F NMR (CDCl₃, 280 MHz): δ (ppm): –81.3 (s, 3F, F-9'), –110.1 to –113.9 (m, 2F, F-4'), –122.1 (m, 2F, F-5'), –123.4 to –123.6 (m, 4F, F-6', F-7'), –126.6 (m, 2F, F-8'); ES (+) *m/z*: [M+Na]⁺ 1894.9, [M+2+Na]²⁺ 959.0; C₇₆H₁₂₂F₁₃NO₃₆.

4.1.6. Boc-homodimer 8. To a solution (0.25 M) in freshly distilled CH₂Cl₂ of **3** (0.400 g, 0.257 mmol) was added under argon the Grubbs catalyst [Cl₂(PCy₃)₂Ru=CHPh] (30 mg, 36 μmol, 14% mol/mol). The solution was stirred at 50 °C and the reaction can be monitored by TLC (Et₂O/MeOH, 90/10). After stirring for 21 h, the solvent was evaporated and the black solid was subjected to column chromatography (SiO₂, Et₂O/MeOH, step gradient: 100/0 to 90/10) to afford **8**. Yield: 60%; *R_f* (Et₂O/MeOH, 75/25)=0.58; mp (dec): 107 °C; [α]_D +136 (*c* 0.825, CHCl₃); IR (cm⁻¹, KBr): 2930 (C–H), 1698 (C=O), 1165 (C–O–C), 1039 (C–N); ¹H NMR (CDCl₃, 500 MHz): δ (ppm): 1.41 (s, 18H, CH₃ Boc), 2.67 (m, 2H, H-6aA), 3.03 (t, 2H, H-4A, ³J_{H-4A/H-5A}=³J_{H-4A/H-3A}=9.0 Hz), 3.11 (dd, 14H, H-2, ³J_{H-2/H-1}=3.0 Hz, ³J_{H-2/H-3}=9.5 Hz), 3.27–3.78 (m, 186H, H-3, H-4, H-5, H-6a, H-6b, 2-OCH₃, 3-OCH₃, 6-OCH₃, H-1'b), 4.01 (m, 2H, H-5A), 4.49 (m, 2H, H-1'a), 4.94 (br s, 2H, H-1A), 5.02 (m, 10H, H-1), 5.09 (m, 2H, H-1), 5.44 (m, 2H, H-2'); ¹³C NMR (CDCl₃, 125 MHz): δ (ppm): 28.9–29.3 (CH₃ Boc), 49.2 (C-6A), 50.8 (C-1'), 58.5–62.2 (2-OCH₃, 3-OCH₃, 6-OCH₃), 70.2–72.1 (C-5, C-6), 79.7 (–O–C– Boc), 80.4–83.1 (C-2, C-3, C-4), 98.7 (C-1A), 99.5–100.8 (C-1), 128.4 (C-2'), 155.4 (–C=O Boc); MALDI-TOF-MS [M+Na]⁺ 3103.4, [M+K]⁺ 3119.3; C₁₃₈H₂₄₂N₂O₇₂.

4.1.7. Procedure for Boc deprotection of 4. A solution of compound **4** (0.150 g, 91.5 μmol) in trifluoroacetic acid (6 mL) was stirred overnight at room temperature. The solution was then diluted with water (30 mL). The organic layer was extracted with dichloromethane (3×20 mL). The combined organic layers were washed with a saturated solution of Na₂CO₃ (60 mL), dried over Na₂SO₄. The solvent was evaporated to afford **9**.

4.1.7.1. Mono-(6^A-deoxy-6^A-non-2-enamino)-hexakis-(6^B,6^C,6^D,6^E,6^F,6^G-O-methyl)-heptakis-(2,3-di-O-methyl)-cyclomaltoheptaose 9. Yield: 94%; *R_f* (Et₂O/MeOH, 85/15)=0.17; mp (dec): 80 °C; [α]_D +130 (*c* 1.000, CHCl₃); IR (cm⁻¹, KBr): 2928 (C–H), 1652 (C=C), 1155 (C–O–C), 1036 (C–N); ¹H NMR (CDCl₃, 500 MHz, assignments by COSY and HSQC): δ (ppm): 0.84 (t, 3H, H-9', ³J_{H-9'/H-8'}=6.5 Hz), 1.13–1.29 (m, 8H, H-5', H-6', H-7', H-8'), 1.98 (q, 2H, H-4', ³J_{H-4'/H-5'}=³J_{H-4'/H-3'}=7.0 Hz), 2.88 (dd, 1H, H-6aA, ²J_{H-6aA/H-6bA}=12.0 Hz, ³J_{H-6aA/H-5A}=6.5 Hz), 3.08–

3.13 (m, 8H, H-2, H-6bA), 3.17–3.33 (m, 20H, H-1', 6-OCH₃), 3.44–3.57 (m, 68H, H-3, H-4, H-6a, H-6b, 2-OCH₃, 3-OCH₃), 3.74–3.79 (m, 7H, H-5), 5.04–5.09 (m, 7H, H-1), 5.46 (m, 1H, H-2'), 5.58 (m, 1H, H-3'); ¹³C NMR (CDCl₃, 125 MHz, assignments by DEPT and HSQC): δ (ppm): 14.4 (C-9'), 22.9 (C-8'), 28.9–29.6 (C-5', C-6'), 32.0 (C-7'), 32.8 (C-4'), 49.6 (C-6A), 51.8 (C-1'), 58.6–61.8 (2-OCH₃, 3-OCH₃, 6-OCH₃), 69.5–71.7 (C-5, C-6), 80.4–83.3 (C-2, C-3, C-4), 99.1–99.6 (C-1), 128.5 (C-2'), 129.3 (C-3'); ES (+) *m/z*: [M+H]⁺ 1538.6, [M+Na]⁺ 1560.6; C₇₁H₁₂₇NO₃₄.

4.1.7.2. Mono-(6^A-deoxy-6^A-(3-phenyl-prop-2-enamino)-hexakis-(6^B,6^C,6^D,6^E,6^F,6^G-O-methyl)-heptakis-(2,3-di-O-methyl)-cyclomaltoheptaose 10. Yield: 82%; *R_f* (Et₂O/MeOH, 90/10)=0.11; mp (dec): 91 °C; [α]_D +137 (*c* 1.050, CHCl₃); IR (cm⁻¹, KBr): 2927 (C–H), 1652 (C=C), 1162 (C–O–C), 1034 (C–N); ¹H NMR (CDCl₃, 500 MHz, assignments by COSY and HSQC): δ (ppm): 3.05 (dd, 1H, H-6aA, ²J_{H-6aA/H-6bA}=11.9 Hz, ³J_{H-6aA/H-5A}=6.5 Hz), 3.15–3.20 (m, 8H, H-2, H-6bA), 3.23–3.39 (m, 18H, 6-OCH₃), 3.51–3.65 (m, 70H, H-3, H-4, H-6a, H-6b, 2-OCH₃, 3-OCH₃, H-1'), 3.79–3.90 (m, 7H, H-5), 5.11–5.15 (m, 7H, H-1), 6.29 (dt, 1H, H-2', ³J_{H-2'/H-1'}=15.6 Hz, ³J_{H-2'/H-1'}=6.2 Hz), 6.55 (d, 1H, H-3', ³J_{H-3'/H-2'}=15.6 Hz), 7.23–7.27 (m, 1H, H_{para}), 7.30 (t, 2H, H_{meta}, ³J_{H_{meta}/H_{para}}=³J_{H_{meta}/H_{ortho}}=7.5 Hz), 7.36 (d, 2H, H_{ortho}, ³J_{H_{ortho}/H_{meta}}=7.5 Hz); ¹³C NMR (CDCl₃, 125 MHz, assignments by DEPT and HSQC): δ (ppm): 50.2 (C-6A), 52.7 (C-1'), 59.2–62.3 (2-OCH₃, 3-OCH₃, 6-OCH₃), 70.5–72.3 (C-5, C-6), 80.6–83.8 (C-2, C-3, C-4), 99.6 (C-1A), 99.7–100.0 (C-1), 127.1 (C_{ortho}), 127.9 (C-3'), 128.4 (C_{para}), 129.4 (C_{meta}), 131.7 (C-2'), 137.6 (C_{ipso}); ES (+) *m/z*: [M+H]⁺ 1530.9, [M+H+Na]²⁺ 777.0; C₇₁H₁₁₉NO₃₄.

4.1.7.3. Mono-(6^A-deoxy-6^A-(5,8-dioxy-non-2-enamino)-hexakis-(6^B,6^C,6^D,6^E,6^F,6^G-O-methyl)-heptakis-(2,3-di-O-methyl)-cyclomaltoheptaose 11. Yield: 94%; *R_f* (Et₂O/MeOH, 80/20)=0.20; mp (dec): 65 °C; [α]_D +107 (*c* 0.500, CHCl₃); IR (cm⁻¹, KBr): 2926 (C–H), 1684 (C=C), 1162 (C–O–C), 1038 (C–N); ¹H NMR (CDCl₃, 500 MHz): δ (ppm): 2.94 (m, 1H, H-6aA), 3.07 (dd, 1H, H-6bA, ²J_{H-6bA/H-6aA}=9.8 Hz, ³J_{H-6bA/H-5A}=3.0 Hz), 3.12 (dd, 7H, H-2, ³J_{H-2/H-1}=3.3 Hz, ³J_{H-2/H-3}=9.3 Hz), 3.17–3.32 (m, 23H, H-1', H-9', 6-OCH₃), 3.43–3.57 (m, 74H, H-3, H-4, H-6a, H-6b, 2-OCH₃, 3-OCH₃, H-3', H-4'), 3.74–3.80 (m, 7H, H-5), 3.93 (d, 2H, H-4', ³J_{H-4'/H-3'}=3.0 Hz), 5.04–5.07 (m, 7H, H-1), 5.73 (m, 2H, H-2', H-3'); ¹³C NMR (CDCl₃, 125 MHz): δ (ppm): 49.3 (C-6A), 50.5–51.2 (C-1'), 58.8–61.9 (2-OCH₃, 3-OCH₃, 6-OCH₃, C-9'), 69.8 (C-6'), 71.3–71.8 (C-5, C-6, C-7'), 72.3 (C-4'), 80.5–83.2 (C-2, C-3, C-4), 99.2–99.5 (C-1), 127.8–128.5 (C-2', C-3'); ES (+) *m/z*: [M+H]⁺ 1542.9, [M+H+Na]²⁺ 783.1; C₆₉H₁₂₃NO₃₆.

4.1.7.4. Mono-(6^A-deoxy-6^A-(3-perfluorohexylprop-2-enamino)-hexakis-(6^B,6^C,6^D,6^E,6^F,6^G-O-methyl)-heptakis-(2,3-di-O-methyl)-cyclomaltoheptaose 12. Yield: 89%; *R_f* (Et₂O/MeOH, 90/10)=0.40; mp (dec): 64 °C; [α]_D +99 (*c* 0.515, CHCl₃); IR (cm⁻¹, KBr): 2932 (C–H), 1653 (C=C), 1242–1191 (C–F), 1146 (C–O–C), 1040 (C–N); ¹H NMR (CDCl₃, 500 MHz): δ (ppm): 3.06 (m, 1H, H-6aA),

3.09–3.20 (m, 8H, H-2, H-6bA), 3.23–3.38 (m, 20H, H-1', 6-OCH₃), 3.51–3.65 (m, 68H, H-3, H-4, H-6a, H-6b, 2-OCH₃, 3-OCH₃), 3.81–3.86 (m, 7H, H-5), 5.10 (d, 3H, H-1, ³J_{H-1/H-2}=2.6 Hz), 5.13 (br s, 4H, H-1), 5.84 (m, 1H, H-3'), 6.50 (d, 1H, H-2', ³J_{H-2'/H-3'}=15.8 Hz); ¹³C NMR (CDCl₃, 125 MHz): δ (ppm): 50.8 (C-6A), 51.5 (C-1'), 59.7–63.5 (2-OCH₃, 3-OCH₃, 6-OCH₃), 69.8–72.9 (C-5, C-6), 81.4–84.4 (C-2, C-3, C-4), 100.3–100.6 (C-1), 108.4–118.7 (C-4', C-5', C-6', C-7', C-8', C-9'), 129.3 (C-3'), 143.4 (C-2'); ¹⁹F NMR (CDCl₃, 280 MHz): δ (ppm): –81.4 (t, 3F, F-9', ³J_{F-9'/F-8'}=9.6 Hz), –110.8 to –113.7 (m, 2F, F-4'), –122.3 (m, 2F, F-5'), –123.5 to –123.8 (m, 4F, F-6', F-7'), –126.8 (m, 2F, F-8'); ES (+) m/z: [M+Na]⁺ 1794.8, [M+H]⁺ 1773.0, [M+2Na]²⁺ 909.0, [M+H+Na]²⁺ 898.0; C₇₁H₁₁₄F₁₃N₃O₃₄.

4.1.7.5. Homodimer 13. Yield: 91%; R_f (Et₂O/MeOH, 70/30)=0.07; mp (dec): 104 °C; [α]_D +140 (c 1.015, CHCl₃); IR (cm⁻¹, KBr): 2926 (C–H), 1654 (C=C), 1163 (C–O–C), 1037 (C–N); ¹H NMR (CDCl₃, 500 MHz): δ (ppm): 2.99 (m, 2H, H-6aA), 3.06 (dd, 2H; H-6bA, ²J_{H-6bA/H-6aA}=9.5 Hz, ³J_{H-6bA/H-5A}=3.0 Hz), 3.12 (dd, 14H, H-2, ³J_{H-2/H-1}=2.5 Hz, ³J_{H-2/H-3}=9.5 Hz), 3.17–3.32 (m, 40H, H-1', 6-OCH₃), 3.43–3.58 (m, 136H, H-3, H-4, H-6a, H-6b, 2-OCH₃, 3-OCH₃), 3.73–3.78 (m, 14H, H-5), 5.04 (d, 8H, H-1, ³J_{H-1/H-2}=2.8 Hz), 5.06 (br s, 6H, H-1), 5.64 (m, 2H, H-2'); ¹³C NMR (CDCl₃, 125 MHz): δ (ppm): 49.5–49.7 (C-6A), 51.8–52.2 (C-1'), 58.5–61.9 (2-OCH₃, 3-OCH₃, 6-OCH₃), 70.5–71.7 (C-5, C-6), 80.5–83.2 (C-2, C-3, C-4), 99.3–99.4 (C-1), 130.6 (C-2'); ES (+) m/z: [M+H]⁺ 2880.7, [M+2H]²⁺ 1441.4, [M+3H]³⁺ 968.6; C₁₂₈H₂₂₆N₂O₆₈.

Acknowledgements

One of us, B.B.G. acknowledges the MRET for financial support. We thank Dr. M. Becchi, IBCP (CNRS) for ESMS and MALDI spectra. We thank Dr. B. Fenet for technical assistance with the NMR analysis.

References and notes

- (a) Grubbs, R. H.; Chang, S. *Tetrahedron* **1998**, *54*, 4413–4450; (b) Trnka, T. M.; Grubbs, R. H. *Acc. Chem. Res.* **2001**, *34*, 18–29; (c) Connon, S. J.; Blechert, S. *Angew. Chem., Int. Ed.* **2003**, *42*, 1900–1923.
- Deiters, A.; Martin, S. F. *Chem. Rev.* **2004**, *104*, 2199–2238.
- Nicolaou, R. C.; Bulger, P. G.; Sarlah, D. *Angew. Chem., Int. Ed.* **2005**, *44*, 4490–4527.
- Astruc, D. *New J. Chem.* **2005**, *29*, 42–56.
- Roy, R.; Das, S. R. *Chem. Commun.* **2000**, 519–529.
- Jorgensen, M.; Hadwiger, P.; Madsen, R.; Stutz, A. E.; Wrodnigg, T. M. *Curr. Org. Chem.* **2000**, *4*, 565–588.
- Chiu, S.-H.; Myles, D. C.; Garrell, R. L.; Stoddart, J. F. *J. Org. Chem.* **2000**, *65*, 2792–2796.
- Lecourt, T.; Mallet, J.-M.; Sinaÿ, P. *Tetrahedron Lett.* **2002**, *43*, 5533–5536.
- Lecourt, T.; Mallet, J.-M.; Sinaÿ, P. *C. R. Chimie* **2003**, *6*, 87–90.
- Lecourt, T.; Mallet, J.-M.; Sinaÿ, P. *Eur. J. Org. Chem.* **2003**, 4553–4560.
- Bistri, O.; Lecourt, T.; Mallet, J.-M.; Sollogouh, M.; Sinaÿ, P. *Chem. Biodivers.* **2004**, *1*, 129–137.
- Perrier, E.; Terry, N.; Rival, D.; Coleman, A. W. *Jpn. Kokai Tokkyo Koho* 2001, Jp 20011323002.
- Coleman, A. W.; Kasselouri, A. *Supramol. Chem.* **1993**, *1*, 155–161.
- Mazzaglia, A.; Donohue, R.; Ravoo, B. J.; Darcy, R. *Eur. J. Org. Chem.* **2001**, 1715–1721.
- Lai, X. H.; Ng, S. C. *J. Chromatogr., A* **2004**, *1031*, 135–142.
- Bodansky, M.; Bodansky, A. *The Practice of Peptide Synthesis*; Springer: Berlin, 1984.
- (a) Mitchell, N. T.; Heesche-Wagner, K. *J. Organomet. Chem.* **1992**, *436*, 43–53; (b) Hooper, R.; Lyons, J. L.; Mapes, K. M.; Schumacher, D.; Moline, D. A.; West, R. *Macromolecules* **2001**, *34*, 931–936.
- Thibaudeau, S.; Fuller, S.; Gouverneur, V. *Org. Biomol. Chem.* **2004**, *2*, 1110–1112.
- Audouard, C.; Fawcett, J.; Griffiths, G. A.; Percy, J. M.; Pintat, S.; Smith, C. A. *Org. Biomol. Chem.* **2004**, *2*, 528–541.
- Chatterjee, A. K.; Morgan, J. P.; Scholl, M.; Grubbs, R. H. *J. Am. Chem. Soc.* **2000**, *122*, 3783–3784.
- Imhof, S.; Randl, S.; Blechert, S. *Chem. Commun.* **2001**, 1692–1693.
- Péroche, S.; Parrot-Lopez, H. *Tetrahedron Lett.* **2003**, *44*, 241–245.
- Krafft, M. P. *Adv. Drug Delivery Rev.* **2001**, *47*, 209–228.
- Péroche, S. Thesis, Université Claude Bernard Lyon 1, France, 2003.
- Kingsbury, J. S.; Harrity, J. P. A.; Bonitatebus, P. J.; Hoveyda, A. H. *J. Am. Chem. Soc.* **1999**, *121*, 791.
- Petter, R. C.; Salek, J. S.; Sikorski, C. T.; Kumaravel, G.; Lin, F.-T. *J. Am. Chem. Soc.* **1990**, *112*, 3860–3868.